

Active substances set

Search phrase: Kidney cancer

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Kidney cancer

Lenvatinib

Lenvatinib is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): - in combination with pembrolizumab, as first-line treatment, - in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)- targeted therapy.



NO REIMBURSEMENT



ESMO

Tivozanib hydrochloride monohydrate

Tivozanib Hydrochloride Monohydrate is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.



NO REIMBURSEMENT



ESMO

Belzutifan

Renal cell carcinoma (RCC) Belzutifan is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.



NO REIMBURSEMENT



ESMO

Pazopanib

Pazopanib is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO

Axitinib


Axitinib is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.


 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**

Nivolumab


Nivolumab as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. Nivolumab in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma. Nivolumab in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.


 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**

Cabozantinib

Cabozantinib is indicated as monotherapy for advanced renal cell carcinoma (RCC): - as first-line treatment of adult patients with intermediate or poor risk, - in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabozantinib, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.

 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**

Pembrolizumab

Pembrolizumab, in combination with axitinib, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. Pembrolizumab, in combination with lenvatinib, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. Pembrolizumab as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**

Ipilimumab

Ipilimumab in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.

 **FULL
REIMBURSEMENT**

 **ESMO**